G Morack

530 total citations
23 papers, 416 citations indexed

About

G Morack is a scholar working on Oncology, Cancer Research and Reproductive Medicine. According to data from OpenAlex, G Morack has authored 23 papers receiving a total of 416 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 7 papers in Cancer Research and 4 papers in Reproductive Medicine. Recurrent topics in G Morack's work include Cancer Treatment and Pharmacology (9 papers), Breast Cancer Treatment Studies (7 papers) and Ovarian cancer diagnosis and treatment (4 papers). G Morack is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), Breast Cancer Treatment Studies (7 papers) and Ovarian cancer diagnosis and treatment (4 papers). G Morack collaborates with scholars based in Germany, United States and Austria. G Morack's co-authors include Thomas Decker, Ute Kettritz, Gϋnter von Minckwitz, G. P. Breitbach, Dirk Elling, Jens‐Uwe Blohmer, Sherko Kümmel, D. Roychowdhury, Jacek Jassem and Suresh H. Advani and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

G Morack

22 papers receiving 402 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
G Morack Germany 9 229 149 76 76 72 23 416
HelenJ. Stewart United Kingdom 9 231 1.0× 334 2.2× 49 0.6× 19 0.3× 183 2.5× 19 777
G. A. T. Hawson Australia 11 136 0.6× 121 0.8× 166 2.2× 182 2.4× 48 0.7× 24 664
Stephen I. Fisher United States 12 84 0.4× 61 0.4× 18 0.2× 152 2.0× 80 1.1× 23 433
Amy Plotkin United States 4 58 0.3× 52 0.3× 45 0.6× 160 2.1× 15 0.2× 5 400
Marisa T. Carriaga United States 6 357 1.6× 190 1.3× 250 3.3× 39 0.5× 115 1.6× 6 771
Paul T. Adams United States 10 435 1.9× 275 1.8× 115 1.5× 76 1.0× 63 0.9× 15 611
Christophe Zemmour France 13 247 1.1× 114 0.8× 141 1.9× 32 0.4× 36 0.5× 51 575
M. Coviello Italy 13 113 0.5× 91 0.6× 56 0.7× 70 0.9× 23 0.3× 26 446
N. Eche France 11 113 0.5× 56 0.4× 61 0.8× 42 0.6× 55 0.8× 25 361
Jonathan Somma United States 9 186 0.8× 76 0.5× 67 0.9× 39 0.5× 9 0.1× 17 336

Countries citing papers authored by G Morack

Since Specialization
Citations

This map shows the geographic impact of G Morack's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G Morack with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G Morack more than expected).

Fields of papers citing papers by G Morack

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G Morack. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G Morack. The network helps show where G Morack may publish in the future.

Co-authorship network of co-authors of G Morack

This figure shows the co-authorship network connecting the top 25 collaborators of G Morack. A scholar is included among the top collaborators of G Morack based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G Morack. G Morack is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Blohmer, Jens‐Uwe, Peter Schmid, J. Hilfrich, et al.. (2010). Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial. Annals of Oncology. 21(7). 1430–1435. 18 indexed citations
2.
Stemmler, Hans‐Joachim, Peter A. Fasching, F. Melchert, et al.. (2007). Gemcitabine and Carboplatin in Intensively Pretreated Patients with Metastatic Breast Cancer. Oncology. 73(5-6). 407–414. 20 indexed citations
3.
Al-Batran, Salah-Eddin, Joachim Bischoff, Gϋnter von Minckwitz, et al.. (2006). The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial. British Journal of Cancer. 94(11). 1615–1620. 59 indexed citations
4.
Kümmel, Sherko, A. Kohls, G. P. Breitbach, et al.. (2006). Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer. British Journal of Cancer. 94(9). 1237–1244. 40 indexed citations
5.
Feher, Olavo, P Vodvářka, Jacek Jassem, et al.. (2005). First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study. Annals of Oncology. 16(6). 899–908. 66 indexed citations
6.
Schmid, Peter, G Morack, V. Heilmann, et al.. (2004). Primary chemotherapy with doxorubicin and paclitaxel in patients with early breast cancer: final results of a multicenter phase II study. Journal of Cancer Research and Clinical Oncology. 130(11). 657–663.
7.
Kettritz, Ute, G Morack, & Thomas Decker. (2004). Stereotactic vacuum-assisted breast biopsies in 500 women with microcalcifications: radiological and pathological correlations. European Journal of Radiology. 55(2). 270–276. 76 indexed citations
8.
Hausmaninger, H., G Morack, Bernhard Heinrich, et al.. (2004). Gemcitabine Combined With Epirubicin in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer. American Journal of Clinical Oncology. 27(4). 429–435. 6 indexed citations
9.
Bauknecht, Thomas, G Morack, C Villena-Heinsen, et al.. (2003). Gemcitabine combined with cisplatin as first-line treatment in patients 60 years or older with epithelial ovarian cancer: a phase II study. International Journal of Gynecological Cancer. 13(2). 130–137. 13 indexed citations
10.
11.
Bauknecht, Thomas, G Morack, C Villena-Heinsen, et al.. (2003). Gemcitabine combined with cisplatin as first-line treatment in patients 60 years or older with epithelial ovarian cancer: a phase II study. International Journal of Gynecological Cancer. 13(2). 130–137. 2 indexed citations
12.
Woywodt, Alexander, et al.. (2000). Necrotizing small-vessel vasculitis confined to the uterine cervix. Seminars in Arthritis and Rheumatism. 29(6). 368–372. 11 indexed citations
13.
14.
Hagen, Anke, et al.. (1996). [Prognostic factors and results of treatment in endometrial carcinoma].. PubMed. 118(3). 154–63. 1 indexed citations
15.
Hagen, Anke, et al.. (1995). [Evaluation of epidemiologic risk factors for endometrial carcinoma based on a case-control study].. PubMed. 117(7). 368–74. 1 indexed citations
16.
Müller, Ulrich, et al.. (1990). [Effectiveness of cisplatin alone and in combination within the scope of primary therapy of ovarian cancer. Results of a prospective multicenter study].. PubMed. 112(7). 421–9. 2 indexed citations
17.
Morack, G, et al.. (1989). [C-reactive protein in the maternal serum and risk of fetal infection in premature rupture of the fetal membranes and threatened premature labor].. PubMed. 111(21). 1404–10. 3 indexed citations
18.
Morack, G, et al.. (1986). [Serum sialic acid levels in cancer, pregnancy and upper respiratory infections].. PubMed. 56(6). 413–7. 5 indexed citations
19.
Morack, G, et al.. (1978). Recent results of in vitro drug prediction in human tumour chemotherapy.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 48(7). 667–72. 4 indexed citations
20.
Morack, G, et al.. (1970). [Heart diseases associated with pregnancy and labor].. PubMed. 92(6). 169–75. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by HelenJ. Stewart Breakdown of academic impact, for papers by G. A. T. Hawson Breakdown of academic impact, for papers by Stephen I. Fisher Breakdown of academic impact, for papers by Amy Plotkin Breakdown of academic impact, for papers by Marisa T. Carriaga Breakdown of academic impact, for papers by Paul T. Adams Breakdown of academic impact, for papers by Christophe Zemmour Breakdown of academic impact, for papers by M. Coviello Breakdown of academic impact, for papers by N. Eche Breakdown of academic impact, for papers by Jonathan Somma
Rankless by CCL
2026